Citigroup Inc Theseus Pharmaceuticals, Inc. Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.12 - $4.18 $6,065 - $11,958	2,861 Added 19073.33%	2,876 $11,000
Q3 2023 Nov 09, 2023	SELL	$2.66 - $10.04 $15,997 - $60,380	-6,014 Reduced 99.75%	15 $0
Q2 2023 Aug 10, 2023	BUY	$7.28 - $11.82 $43,891 - $71,262	6,029 New	6,029 $56,000
Q4 2022 Feb 09, 2023	SELL	$4.69 - $8.36 $665 - $1,187	-142 Reduced 55.25%	115 $0
Q3 2022 Nov 10, 2022	SELL	$5.7 - $8.68 $5,221 - $7,950	-916 Reduced 78.09%	257 $1,000
Q2 2022 Aug 10, 2022	BUY	$5.04 - $14.05 $3,648 - $10,172	724 Added 161.25%	1,173 $6,000
Q1 2022 May 12, 2022	SELL	$8.75 - $14.51 $23,607 - $39,147	-2,698 Reduced 85.73%	449 $5,000
Q4 2021 Feb 10, 2022	BUY	$8.98 - $20.09 $28,260 - $63,223	3,147 New	3,147 $40,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.